STOCK TITAN
  1. Home
  2. News
  3. OPGN

Opgen Inc - OPGN STOCK NEWS

Welcome to our dedicated news page for Opgen (Ticker: OPGN), a resource for investors and traders seeking the latest updates and insights on Opgen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Opgen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Opgen's position in the market.

News
OpGen Announces Acquisition of Preferred Stock by David Lazar
Rhea-AI Summary
OpGen secures $3 million investment from David Lazar, appoints new board of directors, and settles outstanding liabilities with EIB. Lazar to become CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
57.89%
Tags
acquisition
-
News
OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
OpGen, Inc. (Nasdaq: OPGN) reported total revenue of $2.35 million for the first nine months of 2023, a significant increase from $1.89 million in the same period of 2022. The company implemented cash management initiatives, including a U.S. operations restructuring by reducing headcount. Additionally, OpGen signed a preferred stock purchase agreement and a warrant inducement agreement with potential strategic and institutional investors in October 2023. However, its subsidiaries Curetis GmbH and Ares Genetics GmbH filed for insolvency under German and Austrian laws, respectively, in November 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
earnings
-
News
OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds
Rhea-AI Summary
OpGen, Inc. enters agreement with existing investor to exercise warrants, raising up to $11.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
173.81%
Tags
none
News
OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
OpGen, Inc. reported total revenue of approximately $1.65 million for the first half of 2023, a 15% increase compared to the same period in 2022. They also signed an R&D collaboration contract extension and a distribution agreement with Fisher Healthcare for the Unyvero A50 platform in the U.S. Total operating expenses decreased in Q2 2023 to approximately $5.9 million. Cash and cash equivalents were approximately $3.2 million as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.26%
Tags
earnings
-
News
OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.6%
Tags
none
-
News
OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
News
OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
earnings
-
News
OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND
Rhea-AI Summary
OpGen's German subsidiary Curetis GmbH has successfully met all milestones under its research and development collaboration agreement with FIND. The collaboration has resulted in the development of an antibiotic stewardship module, a 'data everywhere' module for mobile and cloud-based data access, and comprehensive next-generation sequencing results. The achievement triggers an additional milestone payment of approximately $0.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.54%
Tags
none
-
News
OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
none
News
OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments
Rhea-AI Summary
OpGen's German subsidiary, Curetis GmbH, has received a batch of ten Unyvero A30 C-Series instruments that have passed testing and are optimized for production and clinical trials. The instruments will enable rapid sample-to-answer molecular testing with various chemistries and assay formats. The C-Series instruments have been improved for manufacturability, serviceability, and robustness, with extended lifetime of key moving parts and reduced manufacturing costs. The company plans to use these instruments for further product development, clinical trials, and regulatory submissions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.59%
Tags
none
Stock OPGN logo
Opgen Inc

Nasdaq:OPGN

OPGN Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

OPGN Stock Data

8.17M
9.98M
5.49%
2.68%
18.52%
Medical Laboratories
Health Care and Social Assistance
Link
US
Gaithersburg

About OPGN

opgen, inc. (nasdaq: opgn) is harnessing the power of informatics and genomic analysis to provide complete solutions for infection prevention and treatment. using our large and ever-growing acuitas lighthouse® knowledgebase of pathogens from around the world, we are developing disruptive technologies aimed to shift the paradigm for managing infectious diseases. today, through our clia-certified clinical laboratory services, we provide rapid detection and analysis of antibiotic resistance and high resolution microbial sequence analysis. our fda-cleared, ivd products rapidly identify pathogens in positive blood cultures.